Peptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges

被引:32
作者
Parrasia, Sofia [1 ]
Szabo, Ildiko [1 ]
Zoratti, Mario [2 ,3 ]
Biasutto, Lucia [2 ,3 ]
机构
[1] Univ Padua, Dept Biol, I-35131 Padua, Italy
[2] CNR Neurosci Inst, I-35131 Padua, Italy
[3] Univ Padua, Dept Biomed Sci, I-35131 Padua, Italy
关键词
peptides; blood-brain-barrier; receptor-mediated transcytosis; cell-penetrating peptides; drug delivery; CELL-PENETRATING PEPTIDES; DENSITY-LIPOPROTEIN RECEPTOR; CENTRAL-NERVOUS-SYSTEM; FOCAL CEREBRAL-ISCHEMIA; IN-VIVO BIODISTRIBUTION; PEG-PLA NANOPARTICLES; GLUTATHIONE PEGYLATED LIPOSOMES; DUAL-FUNCTIONAL NANOPARTICLES; PSD-95 INHIBITOR UCCB01-144; TIGHT JUNCTION MODULATOR;
D O I
10.1021/acs.molpharmaceut.2c00523
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Central nervous system (CNS) diseases are among the most difficult to treat, mainly because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach the brain at concentrations adequate to exert a pharmacological activity. The obstacle posed by the BBB has led to the in-depth study of strategies allowing the brain delivery of CNS-active drugs. Among the most promising strategies is the use of peptides addressed to the BBB. Peptides are versatile molecules that can be used to decorate nanoparticles or can be conjugated to drugs, with either a stable link or as pro-drugs. They have been used to deliver to the brain both small molecules and proteins, with applications in diverse therapeutic areas such as brain cancers, neurodegenerative diseases and imaging. Peptides can be generally classified as receptor-targeted, recognizing membrane proteins expressed by the BBB microvessels (e.g., Angiopep2, CDX, and iRGD), "cell-penetrating peptides" (CPPs; e.g. TAT(47-57), SynB1/3, and Penetratin), undergoing transcytosis through unspecific mechanisms, or those exploiting a mixed approach. The advantages of peptides have been extensively pointed out, but so far few studies have focused on the potential negative aspects. Indeed, despite having a generally good safety profile, some peptide conjugates may display toxicological characteristics distinct from those of the peptide itself, causing for instance antigenicity, cardiovascular alterations or hemolysis. Other shortcomings are the often brief lifetime in vivo, caused by the presence of peptidases, the vulnerability to endosomal/lysosomal degradation, and the frequently still insufficient attainable increase of brain drug levels, which remain below the therapeutically useful concentrations. The aim of this review is to analyze not only the successful and promising aspects of the use of peptides in brain targeting but also the problems posed by this strategy for drug delivery.
引用
收藏
页码:3700 / 3729
页数:30
相关论文
共 498 条
  • [31] The identification of leptin-derived peptides that are taken up by the brain
    Barrett, Graham L.
    Trieu, Jennifer
    Naim, Tim
    [J]. REGULATORY PEPTIDES, 2009, 155 (1-3) : 55 - 61
  • [32] Peptide-lipid nanoconstructs act site-specifically towards glioblastoma growth impairment
    Basso, Joao
    Mendes, Maria
    Silva, Jessica
    Sereno, Jose
    Cova, Tania
    Oliveira, Rui
    Fortuna, Ana
    Castelo-Branco, Miguel
    Falcao, Amilcar
    Sousa, Joao
    Pais, Alberto
    Vitorino, Carla
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2020, 155 : 177 - 189
  • [33] Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery
    Belhadj, Zakia
    Ying, Man
    Cao, Xie
    Hu, Xuefeng
    Zhan, Changyou
    Wei, Xiaoli
    Gao, Jie
    Wang, Xiaoyi
    Yan, Zhiqiang
    Lu, Weiyue
    [J]. JOURNAL OF CONTROLLED RELEASE, 2017, 255 : 132 - 141
  • [34] Mfsd2a is critical for the formation and function of the blood-brain barrier
    Ben-Zvi, Ayal
    Lacoste, Baptiste
    Kur, Esther
    Andreone, Benjamin J.
    Mayshar, Yoav
    Yan, Han
    Gu, Chenghua
    [J]. NATURE, 2014, 509 (7501) : 507 - +
  • [35] Structural Elucidation of the Cell-Penetrating Penetratin Peptide in Model Membranes at the Atomic Level: Probing Hydrophobic Interactions in the Blood-Brain Barrier
    Bera, Swapna
    Kar, Rajiv K.
    Mondal, Susanta
    Pahan, Kalipada
    Bhunia, Anirban
    [J]. BIOCHEMISTRY, 2016, 55 (35) : 4982 - 4996
  • [36] Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1
    Bertrand, Y.
    Currie, J-C
    Poirier, J.
    Demeule, M.
    Abulrob, A.
    Fatehi, D.
    Stanimirovic, D.
    Sartelet, H.
    Castaigne, J-P
    Beliveau, R.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 105 (11) : 1697 - 1707
  • [37] Betterton RD, 2021, HANDB EXP PHARMACOL, V266, P301, DOI 10.1007/164_2021_448
  • [38] Strategies to target bioactive molecules to subcellular compartments. Focus on natural compounds
    Biasutto, Lucia
    Mattarei, Andrea
    La Spina, Martina
    Azzolini, Michele
    Parrasia, Sofia
    Szabo, Ildiko
    Zoratti, Mario
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 181
  • [39] Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability
    Bilsky, EJ
    Egleton, RD
    Mitchell, SA
    Palian, MM
    Davis, P
    Huber, JD
    Jones, H
    Yamamura, HI
    Janders, J
    Davis, TP
    Porreca, F
    Hruby, VJ
    Polt, R
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (13) : 2586 - 2590
  • [40] Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease
    Birolini, Giulia
    Valenza, Marta
    Ottonelli, Ilaria
    Passoni, Alice
    Favagrossa, Monica
    Duskey, Jason T.
    Bombaci, Mauro
    Vandelli, Maria Angela
    Colombo, Laura
    Bagnati, Renzo
    Caccia, Claudio
    Leoni, Valerio
    Taroni, Franco
    Forni, Flavio
    Ruozi, Barbara
    Salmona, Mario
    Tosi, Giovanni
    Cattaneo, Elena
    [J]. JOURNAL OF CONTROLLED RELEASE, 2021, 330 : 587 - 598